Enterome Bioscience, a France-based company developing drugs and diagnostics based on the gut microbiome, received €14.5m ($16.3m) in series C financing on Wednesday from backers including pharmaceutical firm Lundbeck and food producer Nestlé.
The corporates, which participated through their Lundbeckfond Ventures and Nestlé Health Science units respectively, were joined by investors including venture capital firm Seventure Partners.
The cash will be used to move Enterome’s lead product candidate, a drug treatment for inflammatory bowel diseases (IBD) known as EB 8018,…
